Aytu Biopharma (AYTU) Receivables - Net (2016 - 2025)
Historic Receivables - Net for Aytu Biopharma (AYTU) over the last 11 years, with Q4 2025 value amounting to $30.9 million.
- Aytu Biopharma's Receivables - Net rose 2172.97% to $30.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $30.9 million, marking a year-over-year increase of 2172.97%. This contributed to the annual value of $32.3 million for FY2025, which is 3747.77% up from last year.
- Latest data reveals that Aytu Biopharma reported Receivables - Net of $30.9 million as of Q4 2025, which was up 2172.97% from $33.2 million recorded in Q3 2025.
- Aytu Biopharma's Receivables - Net's 5-year high stood at $35.8 million during Q1 2025, with a 5-year trough of $21.6 million in Q3 2021.
- Over the past 5 years, Aytu Biopharma's median Receivables - Net value was $28.8 million (recorded in 2021), while the average stood at $28.3 million.
- As far as peak fluctuations go, Aytu Biopharma's Receivables - Net skyrocketed by 43834.55% in 2021, and later crashed by 2582.76% in 2024.
- Quarter analysis of 5 years shows Aytu Biopharma's Receivables - Net stood at $23.0 million in 2021, then rose by 11.13% to $25.5 million in 2022, then grew by 15.09% to $29.4 million in 2023, then dropped by 13.6% to $25.4 million in 2024, then rose by 21.73% to $30.9 million in 2025.
- Its Receivables - Net stands at $30.9 million for Q4 2025, versus $33.2 million for Q3 2025 and $31.2 million for Q2 2025.